Last results 13 Oct 2026
Johnson & Johnson
I · AI Analysis
The brief
Johnson & Johnson is a global healthcare company operating in two main segments: Innovative Medicine (prescription drugs) and MedTech (surgical, orthopedic, cardiovascular, and vision products) [Yahoo Finance]. The company reported third-quarter 2026 sales of $25.4 billion, up 5.9%, and raised its full-year sales guidance to $101.0–$101.4 billion [Stockwatch]. Recent insider activity shows $67.8 million in open-market sales by five executives, including $44.7 million from CEO Joaquin Boix Duato, with no open-market purchases [SEC Form 4].
Johnson & Johnson is financially healthy with strong margins, manageable debt, and consistent cash generation [Sentinellis calculation].
Sentinellis health
Financially healthy
8.6/10
7.5+ strong · 4.5–7.5 moderate · under 4.5 weak
Profitability
Returns on capital
Growth & momentum
Balance sheet
Cash generation
Value creation
Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.
Market capitalisation
$606.4B
Revenue (TTM)
$97.9B
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
2 stories · ranked by relevance
- Company2026-10-13
Johnson & Johnson Q3 Sales $25.4B (+5.9%); Raises 2026 Guidance
Stockwatch
- Company2026-10-12
New TREMFYA® study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
Investing News Network (inn)
Premium · Free with any account
Five executives sold $67.8 million on the open market in the past 90 days, with no insider purchases; CEO Joaquin Boix Duato accounted for $44.7 million of these sales across two transactions [SEC Form 4].
Risks
3
Opportunities
5
Red flags
1
Leadership
10
8 more findings in the full report — free with any account.
Unlock the full Johnson & Johnson analysis
Create a free account to access the complete AI-generated report with inline citations.
- 3 risks, 5 opportunities and 1 red flag — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?